Dr Jag Shur, Vice-President, Science & Technology and Co-Founder at Nanopharm, an Aptar Pharma company, is an internationally recognised expert in the investigation of the bioequivalence of OINDPs. Holding a BSc (Hons) in Chemistry, he completed his PhD entitled “Formulated Muco-Regulatory Agents in the Airways of Patients with Cystic Fibrosis” at Portsmouth School of Pharmacy in the UK. Dr Shur is also a post-doctoral fellow at the UCL School of Pharmacy (London, UK), having investigated the fabrication of micro particles for vaccine delivery using supercritical fluid technology.